Početna stranicaJNJ • NYSE
add
Johnson & Johnson
Preth. zaklj. cijena
146,82 $
Dnevni raspon
148,00 $ - 153,45 $
Godišnji raspon
140,68 $ - 168,85 $
Tržišna kapitalizacija
367,88 mlr. USD
Prosječna količina
9,00 mil.
P/E omjer
26,41
Prinos dividende
3,24 %
Glavno tržište vrijednosnica
NYSE
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 22,52 mlr. | 5,26 % |
Operativni troškovi | 11,75 mlr. | 18,10 % |
Neto dohodak | 3,43 mlr. | −15,26 % |
Neto profitabilnost | 15,24 | −19,45 % |
Zarada po dionici | 2,04 | −10,92 % |
EBITDA | 5,49 mlr. | −11,36 % |
Efektivna porezna stopa | 11,73 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 20,30 mlr. | −11,47 % |
Ukupna imovina | — | — |
Ukupne obveze | — | — |
Ukupni kapital | 70,16 mlr. | — |
Dionice u optjecaju | 2,41 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 5,04 | — |
Povrat imovine | — | — |
Povrat kapitala | 8,59 % | — |
Tok novca
Neto promjena novca
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 3,43 mlr. | −15,26 % |
Gotovina od poslovanja | — | — |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | — | — |
Slobodan tok novca | — | — |
Više
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 40 on the 2023 Fortune 500 list of the largest United States corporations. In 2023, the company was ranked 40th in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 130,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato.
Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready-to-use sterile surgical dressings. In 2023, the company split-off its consumer healthcare business sector into a new publicly traded company, Kenvue. The company is exclusively focused on developing and producing pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA. Wikipedia
Glavni izvršni direktor
Osnovano
sij 1886
Web-lokacija
Zaposlenici
131.900
